drugset / Trial / NCT07220629
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
RandomizedParallel-groupTriple-blindTreatment
Summary
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
Timeline
- Start
- 2025-10-02
- Primary completion
- 2026-08-21
- Completion
- 2026-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NT-0796 | Small molecule | — | Oral |